Insider Selling: Crispr Therapeutics AG (CRSP) Insider Sells 15,000 Shares of Stock

Crispr Therapeutics AG (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $20.55, for a total transaction of $308,250.00. Following the completion of the sale, the insider now directly owns 115,204 shares of the company’s stock, valued at approximately $2,367,442.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Tyler Dylan-Hyde also recently made the following trade(s):

  • On Tuesday, January 2nd, Tyler Dylan-Hyde sold 38,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $21.64, for a total transaction of $822,320.00.
  • On Friday, December 28th, Tyler Dylan-Hyde sold 700 shares of Crispr Therapeutics stock. The stock was sold at an average price of $21.75, for a total transaction of $15,225.00.
  • On Friday, December 29th, Tyler Dylan-Hyde sold 31,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $22.72, for a total transaction of $704,320.00.
  • On Friday, December 15th, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.90, for a total transaction of $283,500.00.

Crispr Therapeutics AG (CRSP) opened at $28.52 on Friday. Crispr Therapeutics AG has a twelve month low of $11.63 and a twelve month high of $30.79.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). The company had revenue of $2.39 million for the quarter, compared to analysts’ expectations of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The business’s revenue for the quarter was up 54.2% compared to the same quarter last year. During the same period last year, the company posted ($2.77) EPS. equities analysts predict that Crispr Therapeutics AG will post -2.46 EPS for the current year.

A number of equities research analysts have recently commented on CRSP shares. Cann reiterated a “hold” rating on shares of Crispr Therapeutics in a research note on Sunday, December 10th. Piper Jaffray Companies began coverage on Crispr Therapeutics in a research note on Friday, December 22nd. They issued an “overweight” rating on the stock. Oppenheimer initiated coverage on Crispr Therapeutics in a research note on Thursday, December 7th. They issued a “hold” rating on the stock. SunTrust Banks reiterated a “hold” rating and set a $16.00 price target on shares of Crispr Therapeutics in a research report on Friday, November 10th. Finally, BidaskClub cut Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Crispr Therapeutics presently has a consensus rating of “Buy” and an average target price of $22.81.

Large investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN raised its holdings in shares of Crispr Therapeutics by 459.7% during the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after acquiring an additional 6,560 shares in the last quarter. Capital Investment Advisory Services LLC bought a new position in shares of Crispr Therapeutics during the third quarter valued at approximately $193,000. Ark Investment Management LLC bought a new position in shares of Crispr Therapeutics during the second quarter valued at approximately $206,000. Moloney Securities Asset Management LLC bought a new position in shares of Crispr Therapeutics during the third quarter valued at approximately $235,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Crispr Therapeutics during the third quarter valued at approximately $288,000. 24.52% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://ledgergazette.com/2018/01/13/crispr-therapeutics-ag-crsp-insider-tyler-dylan-hyde-sells-15000-shares.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply